>What Companies do you think Cox is talking to with respect to a potential partnership in the US for Atryn?<
The most logical US ATryn partners (IMO) are NVO and WYE. These companies already have a salesforce for one or more large-selling plasma-protein drugs.
GTC recently hired a business-development executive, Ashley Lawton, PhD (#msg-18432652). Dr. Lawton (rather than Dr. Cox) is probably the one leading partnership discussions.
>Assuming Atryn gets approval in the US wouldn't it make the most economic sense for a potential partner to just purchase all of GTCB ($2-4/pps) vs. some type of upfront money ($20-50 million) and profit sharing?<
I doubt that GTC’s BoD would seriously consider $2/share. If an offer came in at $4/share, the BoD would presumably put the offer up for a shareholder vote.
Even if a buyout offer were turned down, it would put a floor under the share price.
>I'm a little surprised with the share price lagging that no one has thrown out a $2-4 takeover offer.<
Market Data 
Markets 
AI
